pancreatic neuroendocrine tumors
Conditions
Interventions
Gold Standard:The previously established subtyping criteria for pancreatic neuroendocrine tumors based on sequencing results, DAXX/ATRX mutation status, and tumor size.
Index test:Preoperative enhanced CT imaging analysis (including traditional imaging feature assessment and radiomics analysis)
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Part One: 1. Surgical pathology confirmed a solitary pancreatic neuroendocrine tumor; 2. There are records of classification into indolent and non-indolent neuroendocrine tumors; 3. Preoperative enhanced CT examination was performed; Part Two: Patients with pancreatic neuroendocrine tumors who underwent surgical treatment or did not undergo surgery but have imaging follow-up records for more than 6 months.
Exclusion criteria
Exclusion criteria: Part One 1. Preoperative non-contrast CT examination; 2. Lesions are not visible on contrast-enhanced CT images or there are image quality issues. Part Two 1. No contrast-enhanced CT images available for analysis; 2. Lesions are not visible on contrast-enhanced CT images or image quality does not meet analysis requirements; 3. Patients who have not undergone surgical treatment with a follow-up period of less than 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CT attenuation values of the lesion in the arterial phase;tumor size;CT attenuation values of the pancreatic parenchyma in the arterial phase;CT attenuation values of the lesion in the unenhanced phase;CT attenuation values pancreatic parenchyma in the portal venous phase;CT attenuation values of the lesion in the portal phase; | — |
Countries
China
Contacts
Public ContactHuadan Xue
Peking Union Medical College Hospital
Outcome results
None listed